Summary & Overview
HCPCS C9084: Injection, loncastuximab tesirine-lpyl, 0.1 mg
HCPCS Level II code C9084 designates the injection of loncastuximab tesirine‑lpyl at 0.1 mg per billing unit, a targeted antibody‑drug conjugate used in oncology. Nationally, this code matters because it captures the drug administration line for a high-cost, specialty oncology therapy and informs payer coverage, utilization, and site-of-service claims reporting. Accurate coding affects reimbursement, clinical billing workflows, and drug‑specific utilization monitoring across outpatient infusion sites.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how this code is used clinically and administratively, typical billing and service contexts, payer coverage landscape, and common modifiers associated with oncology drug administration. The publication also outlines benchmarks and policy considerations relevant to high-cost oncology injectables, claims documentation expectations, and implications for outpatient infusion centers.
This summary provides operational context for revenue cycle, clinical informatics, and oncology practice managers seeking clarity on HCPCS Level II code C9084, including where the service is commonly performed and what kinds of reporting and payer interactions to anticipate. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9084 represents an injection of loncastuximab tesirine-lpyl, dosed at 0.1 mg per billing unit. This code denotes the administration of a targeted antibody‑drug conjugate used in oncology treatment.
Service Type: Drug administration / oncology infusion
Typical Site of Service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving C9084 is an adult with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or other eligible B-cell malignancy who is receiving intravenous loncastuximab tesirine-lpyl as targeted antibody–drug conjugate therapy. The clinical workflow begins with oncology evaluation, review of prior therapies, and confirmation of indication. Pre-infusion orders include chemotherapy consent, baseline labs (CBC with differential, CMP, liver function tests), and assessment for infusion reactions. On the day of service the oncology nurse performs verification, establishes intravenous access, and administers the dose calculated from vial strength (billing unit: 0.1 mg). Vital signs and observation for infusion-related adverse events occur during and after administration; post-infusion monitoring and follow-up visits document response, toxicities, and any required dose modifications or supportive care (antiemetics, growth factors, transfusions). Administration commonly occurs in an outpatient hospital infusion center or oncology clinic with chemo-certified staff; occasions for inpatient administration include severe tumor burden requiring close monitoring or management of complications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |